Evaluation of the protection of primates transfused with variant Creutzfeldt-Jakob disease-infected blood products filtered with prion removal devices: A 5-year update

Transfusion

Volumn 55, Issue 6, 2015, Pages 1231-1241

  Lescoutra Etchegaray, Nathalie ^a   Jaffré, Nina ^a   Sumian, Chryslain ^b   Durand, Valérie ^c   Correia, Evelyne ^c   Mikol, Jacqueline ^c   Luccantoni Freire, Sophie ^c   Culeux, Audrey ^a   Deslys, Jean Philippe ^c   Comoy, Emmanuel E ^c  

^a Macopharma   (France)

^b MacoPharma   (France)

^c CEA DSV iMETI SEPIA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PRION PROTEIN; PROTEASE RESISTANT PRION PROTEIN; PROTEINASE; UNCLASSIFIED DRUG; MICROSPHERE; PRION; RESIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BLOOD COMPATIBILITY; BLOOD FILTER; BLOOD FILTRATION; BLOOD SAFETY; BLOOD SAMPLING; BLOOD TRANSFUSION; CONTROLLED STUDY; DIAGNOSTIC TEST; LEUKAPHERESIS; LYMPH NODE BIOPSY; MACACA FASCICULARIS; MALE; NEUROLOGIC DISEASE; NONHUMAN; PRIMATE; PRION; PRION DISEASE; PRION REDUCTION FILTER; VARIANT CREUTZFELDT JAKOB DISEASE; VIRUS INFECTIVITY; VIRUS TRANSMISSION; ADSORPTION; ADVERSE EFFECTS; ANALYSIS; ANIMAL; BLOOD COMPONENT THERAPY; BLOODBORNE BACTERIUM; BOVINE; BRAIN CHEMISTRY; CHEMISTRY; CREUTZFELDT-JAKOB SYNDROME; DEVICES; ENCEPHALOPATHY, BOVINE SPONGIFORM; EVALUATION STUDY; ISOLATION AND PURIFICATION; MICROPORE FILTER; PROCEDURES; SPINAL CORD; SPLEEN; TOXICITY; TRANSMISSION; ULTRAFILTRATION;

ADSORPTION; ANIMALS; BLOOD COMPONENT TRANSFUSION; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; BRAIN CHEMISTRY; CATTLE; CREUTZFELDT-JAKOB SYNDROME; ENCEPHALOPATHY, BOVINE SPONGIFORM; LEUKOCYTE REDUCTION PROCEDURES; MACACA FASCICULARIS; MALE; MICROPORE FILTERS; MICROSPHERES; PRIONS; RESINS, SYNTHETIC; SPINAL CORD; SPLEEN; ULTRAFILTRATION;

EID: 84930866664     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12999     Document Type: Article

References (26)

1. Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull 2003;66:255-65.
2. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363:417-21.
3. Hewitt PE, Llewelyn CA, Mackenzie J, et al. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components. Vox Sang 2006;91:348.
4. Gillies M, Chohan G, Llewelyn CA, et al. A retrospective case note review of deceased recipients of vCJD-implicated blood transfusions. Vox Sang 2009;97:211-8.
5. Gill ON, Spencer Y, Richard-Loendt A, et al. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ 2013;347:f5675.
6. Anderson RM, Donnelly CA, Ferguson NM, et al. Transmission dynamics and epidemiology of BSE in British cattle. Nature 1996;382:779-88.
7. Smith PG, Bradley R. Bovine spongiform encephalopathy (BSE) and its epidemiology. Br Med Bull 2003;66:185-98.
8. Gregori L, McCombie N, Palmer D, et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 2004;364:529-31.
9. Cardone F, Sowemimo-Coker S, Abdel-Haq H, et al. Assessment of prion reduction filters in decreasing infectivity of ultracentrifuged 263K scrapie-infected brain homogenates in "spiked" human blood and red blood cells. Transfusion 2014;54:990-5.
10. Sowemimo-Coker SO, Demczyk CA, Andrade F, et al. Evaluation of removal of prion infectivity from red blood cells with prion reduction filters using a new rapid and highly sensitive cell culture-based infectivity assay. Transfusion 2010;50:980-8.
11. Gregori L, Gurgel PV, Lathrop JT, et al. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 2006;368:2226-30.
12. Gregori L, Lambert BC, Gurgel PV, et al. Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands. Transfusion 2006;46:1152-61.
13. Lescoutra-Etchegaray N, Sumian C, Culeux A, et al. Removal of exogenous prion infectivity in leukoreduced red blood cells unit by a specific filter designed for human transfusion. Transfusion 2014;54:1037-45.
14. Elebute MO, Choo L, Mora A, et al. Transfusion of prionfiltered red cells does not increase the rate of alloimmunization or transfusion reactions in patients: results of the UK trial of prion-filtered versus standard red cells in surgical patients (PRISM A). Br J Haematol 2013;160:701-8.
15. Cancelas JA, Rugg N, Pratt PG, et al. Infusion of P-Capt prion-filtered red blood cell products demonstrate acceptable in vivo viability and no evidence of neoantigen formation. Transfusion 2011;51:2228-36.
16. Cahill MR, Murphy T, Khan M, et al. Phase I/II safety study of transfusion of prion-filtered red cell concentrates in transfusion-dependent patients. Vox Sang 2010;99:174-6.
17. Murphy CV, Eakins E, Fagan J, et al. In vitro assessment of red-cell concentrates in SAG-M filtered through the Maco- Pharma P-CAPT prion-reduction filter. Transfus Med Oxf Engl 2009;19:109-16.
18. Herzog C, Rivière J, Lescoutra-Etchegaray N, et al. PrPTSE distribution in a primate model of variant, sporadic, and iatrogenic Creutzfeldt-Jakob disease. J Virol 2005;79:14339-45.
19. Herzog C, Salès N, Etchegaray N, et al. Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. Lancet 2004;363:422-8.
20. Comoy EE, Casalone C, Lescoutra-Etchegaray N, et al. Atypical BSE (BASE) transmitted from asymptomatic aging cattle to a primate. PloS One 2008;3:e3017.
21. Lasmezas CI, Deslys JP, Demaimay R, et al. BSE transmission to macaques. Nature 1996;381:743-4.
22. Lasmezas CI, Fournier JG, Nouvel V, et al. Adaptation of the bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt-Jakob disease: implications for human health. Proc Natl Acad Sci U S A 2001;98:4142-7.
23. Lasmezas CI, Comoy E, Hawkins S, et al. Risk of oral infection with bovine spongiform encephalopathy agent in primates. Lancet 2005;365:781-3.
24. Mead S, Wadsworth JD, Porter MC, et al. Variant Creutzfeldt-Jakob disease with extremely low lymphoreticular deposition of prion protein. JAMA Neurol 2014;71:340-3.
25. National CJD Research & Surveillance Unit, University of Edinburgh. Creutzfeldt-Jakob disease in the UK (by calendar year). Edinburgh: The University of Edinburgh; 2014 [cited 2014 Oct 27]. Available from: http://www.cjd.ed.ac.uk/documents/figs.pdf.
26. Institut de Veille Sanitaire (INVS). CJD - number of cases in France. Saint-Maurice: INVS France; 2014 [cited 2014 Oct 27]. Available from: http://www.invs.sante.fr/Dossiers-thematiques/Maladies-infectieuses/Risques-infectieux-d-origine-alimentaire/Maladie-de-Creutzfeldt-Jakob/Donneesepidemiologiques.